Novel transient outward and ultra-rapid delayed rectifier current antagonist, AVE0118, protects against ventricular fibrillation induced by myocardial ischemia.

AVE0118 is a novel drug that blocks the transient outward current (Ito), the ultra rapid component of the delayed rectifier current (IKur), and the acetylcholine dependent potassium channel (IKach). The latter 2 channels are more abundant in atrial tissue. It is possible that AVE0118 could reduce regional differences in repolarization and thereby prevent malignant arrhythmias provoked by ischemia. To test this hypothesis, ventricular fibrillation was induced by a 2-minute occlusion of the left circumflex coronary artery during the last min of exercise in dogs with healed myocardial infarctions (n = 9). On a subsequent day, this exercise plus ischemia test was repeated after pretreatment with AVE0118 (1.0 mg/kg, IV). AVE0118 did not change QTc (Van de Water's correction) interval [245 +/- 6.0 ms (control) versus 242 +/- 2.3 ms (AVE)] and attenuated the dispersion of repolarization as measured by the duration of the descending portion of the T wave (Tpeak - Tend) induced by ischemia [ischemic changes: +11.1 +/- 2.4 ms (no drug) versus +2.2 +/- 3.7 ms (AVE)]. AVE0118 also significantly reduced the incidence of ventricular fibrillation, protecting 7 of 9 animals. Thus, AVE0118 abolished ischemically induced repolarization abnormalities and prevented malignant arrhythmias induced by ischemia without altering QTc interval.

Citation

George E Billman, Monica Kukielka. Novel transient outward and ultra-rapid delayed rectifier current antagonist, AVE0118, protects against ventricular fibrillation induced by myocardial ischemia. Journal of cardiovascular pharmacology. 2008 Apr;51(4):352-8

Mesh Tags

Substances

PMID: 18427277

search → result